ClinicalTrials.gg
RecruitingNCT07584226Updated Nov 3, 2026

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

A Phase 1/2 interventional study of RLY-8161 in Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors and NRAS Mutation, sponsored by Relay Therapeutics, Inc.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Relay Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 3, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,341 studies in Colorectal Neoplasms with a site in United States — 417 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
554th of 1,933
180 · median 64
Started
2026
with 118 others
Phase 1/2
266 of 2,341
68 open now
Primary completion
2029-05
later than 529 of 627 live
Registered
2,282nd of 2,341
by date

Among the 2,341 studies in Colorectal Neoplasms with a site in United States, this one is the 554th largest by planned enrollment of the 1,933 interventional ones that give a count, is one of 119 that started in 2026, is one of 266 in phase 1/2, reaches primary completion later than 529 of the 627 other live ones, and was the 2,282nd registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

417 of the 2,341 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 417 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,341 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma, colorectal and other solid tumors.

Read the detailed description

This is a Phase 1/2 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma, colorectal and other solid tumors. This study consists of 2 parts: dose escalation (Part 1) and dose expansion (Part 2).

Part 1, dose escalation will explore multiple ascending doses of RLY-8161 in participants with any advanced NRAS-mutant solid tumor until maximum tolerated dose (MTD) is reached or one or more recommended Phase 2 dose (RP2D) is identified.

Part 2, dose expansion will be at the RP2D(s) identified in Part 1 in NRAS-mutant solid tumors.

03

Conditions studied

  • Advanced NRAS-Mutant Melanoma
  • Advanced NRAS-Mutant Solid Tumors
  • NRAS Mutation
  • NRAS G12D
  • NRAS G13R
  • NRAS G13D
  • NRAS G12V
  • NRAS Q61R
  • NRAS Q61K
  • NRAS Q61L
  • NRAS Q61H
  • Advanced NRAS-mutant Colorectal Cancer
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status of 0 to 1.
  • confirmed diagnosis of unresectable Stage III or IV melanoma or other solid tumor.
  • Disease is to standard therapy (including targeted therapy), participant is intolerant of standard therapy, or participant has declined standard therapy.
  • per (RECIST) v1.1.
  • One or more documented primary oncogenic NRAS mutation(s).

Exclusion criteria

Exclusion Criteria:

  • Known activating KRAS, HRAS, BRAF, or EGFR mutation or known alterations in other driver oncogenes that are recognized as actionable oncogenic drivers for the participant's specific tumor type.
  • Prior treatment with ERK, MEK, RAF, or RAS targeting agents or any agent whose mechanism of action is to inhibit the RAS-MAPK pathway.
  • For participants with melanoma: lactate dehydrogenase (LDH) >2×.
  • Central nervous system (CNS) associated with progressive neurologic symptoms or requiring ongoing to control the CNS disease.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Part 1: RLY-8161 for participants with advanced NRAS-mutant solid tumors

    Multiple doses of RLY-8161 for oral administration

    Drug: RLY-8161

  • Experimental
    Part 2: RLY-8161 for participants with advanced NRAS-mutant solid tumors

    Oral doses of RLY-8161 as determined during Part 1 Dose Escalation

    Drug: RLY-8161

Interventions

  • DrugRLY-8161

    RLY-8161 is an NRAS-selective inhibitor

06

What researchers measure

Primary outcomes

  1. Part 1: Maximum Tolerated Dose (MTD) and/or RP2D of RLY-8161

    Time frame: Cycle 1 (28-day cycle) of treatment for MTD and at the end of every cycle (28-day cycle) for RP2D until treatment discontinuation, approximately 12 months

  2. Part 1: Number of participants with Adverse Events (AEs) or Serious Adverse Events (SAEs), with changes in vital signs, electrocardiograms (ECGs), and laboratory tests

    Time frame: Cycle 1 (28-day cycle) of treatment and at the end of every cycle (28-day cycle) until 30 days after treatment discontinuation, approximately 13 months

  3. Part 2: Objective Response Rate (ORR) of RLY-8161 as assessed by RECIST v1.1

    Time frame: Approximately every 8 weeks on treatment and every 12 weeks after last dose in the absence of progressive disease, approximately 18 months

Secondary outcomes

  1. Part 1 and Part 2: Changes in NRAS mutant allele fraction in circulating tumor DNA (ctDNA)

    Time frame: Approximately every 2 weeks in Cycle 1 (28-day cycle), at the beginning of Cycle 2 (28-day cycle), and at the beginning of every odd cycle (28-day cycle) until End of Treatment (EOT), approximately 12 months

  2. Part 1 and Part 2: Plasma concentration and PK parameters of RLY-8161

    Time frame: Approximately every 2 weeks in Cycle 1 (28-day cycle) and at Day 1 of every cycle (28-day cycle) through Cycle 4

  3. Part 1: ORR of RLY-8161 as assessed by RECIST v1.1

    Time frame: Approximately every 8 weeks on treatment and every 12 weeks after last dose in the absence of progressive disease, approximately 18 months

  4. Part 1 and 2: Duration of Response (DOR) of RLY-8161 as assessed by RECIST v1.1

    Time frame: Approximately every 8 weeks on treatment and every 12 weeks after last dose in the absence of progressive disease, approximately 18 months

  5. Part 1 and 2: Disease Control Rate (DCR) of RLY-8161 as assessed by RECIST v1.1

    Time frame: Approximately every 8 weeks on treatment and every 12 weeks after last dose in the absence of progressive disease, approximately 18 months

  6. Part 2: Progression-free survival (PFS) as assessed by RECIST v1.1

    Time frame: Approximately every 8 weeks on treatment and every 12 weeks after last dose in the absence of progressive disease, approximately 18 months

  7. Part 2: Overall Survival

    Time frame: Cycle 1 (28-day cycles) until study completion, approximately 30 months

  8. Part 2: Number of participants with AEs or SAEs, with changes in vital signs, ECGs, and laboratory tests

    Time frame: Cycle 1 (28-day cycle) of treatment and at the end of every cycle (28-day cycle) until 30 days after treatment discontinuation, approximately 13 months

07

Study locations

9 of 9 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2029, 38 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 38 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2027 → May 2029 and completion Dec 2029 → Jun 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 13, 2026
StartActual
Mar 9, 2026
Primary completionEst.
May 31, 2029was Dec 2027
CompletionEst.
Jun 30, 2031was Dec 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2027→May 31, 2029
Nov 3, 2026
Study completion
Dec 31, 2029→Jun 30, 2031
Nov 3, 2026
Enrollment
35→180
Nov 3, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedKnown activating KRAS, HRAS, BRAF, or BRAFEGFR mutation or known alterations in other driver oncogenes that are recognized as actionable oncogenic drivers for the participant's specific tumor type.
  • EditedCentral nervous system (CNS) metastases that are associated with progressive neurologic symptoms or requirerequiring ongoing corticosteroids to control the CNS disease.
Nov 3, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPart 1 and Part 2: Changes in NRAS mutant allele fraction in circulating tumor DNA (ctDNA)Time frame: Approximately every 2 weeks in Cycle 1 (28-day cycle), at the beginning of Cycle 2 (28-day cycle), and at the beginning of every odd cycle (28-day cycle) until End of Treatment (EOT), approximately 12 months
Nov 3, 2026
Design
Added Phase 2
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Dec 30, 2027→May 31, 2029
    Study completion Dec 31, 2029→Jun 30, 2031
    Enrollment 35→180
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedKnown activating KRAS, HRAS, BRAF, or BRAFEGFR mutation or known alterations in other driver oncogenes that are recognized as actionable oncogenic drivers for the participant's specific tumor type.
    • EditedCentral nervous system (CNS) metastases that are associated with progressive neurologic symptoms or requirerequiring ongoing corticosteroids to control the CNS disease.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPart 1 and Part 2: Changes in NRAS mutant allele fraction in circulating tumor DNA (ctDNA)Time frame: Approximately every 2 weeks in Cycle 1 (28-day cycle), at the beginning of Cycle 2 (28-day cycle), and at the beginning of every odd cycle (28-day cycle) until End of Treatment (EOT), approximately 12 months
    Design Added Phase 2
    + 3 other changes: verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07584226
Lead sponsor
Relay Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Mar 9, 2026
Primary completion
May 31, 2029 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

Relay Therapeutics, Inc
Contact
ClinicalTrials@relaytx.com
617-322-0731

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion